Conversion of Anti-Coagulants to Heparin Before and After Elective Surgery — CPB 0200 | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0200 covering conversion of anti-coagulants to heparin before and after elective surgery, effective 2026-03-26. Billing teams who handle heparin infusion claims under HCPCS codes J1642, J1643, J1644, and S9336 need to review their documentation and charge capture against updated medical necessity criteria now.

This coverage policy governs how Aetna handles anti-coagulation bridging for members on apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), rivaroxaban (Xarelto), or warfarin who need elective surgery or diagnostic procedures. The policy sets clear boundaries on when inpatient bridging is medically necessary versus when outpatient weaning is sufficient. Getting that line wrong means claim denial.

Quick-Reference Table

Aetna Anti-Coagulant Bridging Coverage Criteria and Medical Necessity Requirements 2026

The Aetna anti-coagulation bridging coverage policy under CPB 0200 in the Aetna system draws a sharp line between two clinical scenarios. Most members can wean off their oral anti-coagulant safely before surgery on an outpatient basis. Aetna's position is that outpatient weaning is the default—not the exception.

Continuous intravenous heparin infusion meets medical necessity when a member is on apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin and needs maintained anti-coagulation before or after a diagnostic or therapeutic procedure. That's the covered use case. The clinical rationale is straightforward: these patients face real thrombotic risk during the perioperative window, and IV heparin bridges that gap.

The tighter question—and the one most likely to drive claim denial—is when inpatient days are medically necessary. Aetna allows up to three inpatient pre-procedure days when "circumstances arise that might compromise the member's state of anti-coagulation such that thrombotic complications may occur." That language is doing a lot of work. Your clinical documentation needs to spell out exactly what those circumstances are for each patient.

This is not a blank authorization for three inpatient days whenever a patient is on blood thinners. Aetna's standard is thrombotic risk that can't be managed outpatient. If your admitting physicians are routinely writing generic bridging orders without patient-specific risk documentation, you're building a claim denial problem. Prior authorization requirements for inpatient days add another layer—verify those before admission, not after.

The good news is that the outpatient scenario is relatively clean. If the member weans off the oral anti-coagulant outpatient and the procedure goes forward without complication, your billing for heparin infusion services under J1644 or S9336 should be straightforward, assuming the underlying anti-coagulation indication is documented with ICD-10 Z79.01.

Coverage Indications at a Glance

Aetna Anti-Coagulant Bridging Billing Guidelines and Action Items 2026

The effective date of 2026-03-26 means this modified policy is already active. If your team hasn't reviewed claims submitted after March 26, do that now.

1. Audit your inpatient pre-procedure bridging claims from March 26, 2026 forward.

Pull any claim that includes J1644 in an inpatient setting tied to a pre-procedure day. Confirm the medical record documents specific thrombotic risk factors—not just that the patient takes warfarin. Generic documentation won't hold up to a medical necessity review.

2. Update your charge capture workflow for HCPCS codes J1642, J1643, and J1644.

These three heparin injection codes have different unit structures. J1642 bills per 10 units (heparin lock flush), J1643 bills per 1,000 units for the Pfizer formulation (not therapeutically equivalent to J1644), and J1644 bills per 1,000 units for standard heparin sodium. Mixing these up is a common claim denial trigger. Make sure your charge capture team knows which product is being administered before selecting the code.

3. Separate S9336 claims carefully for home infusion billing.

S9336 covers home infusion therapy for continuous anti-coagulant infusion—the administrative services component. This code is covered when selection criteria are met, but home infusion reimbursement under Aetna varies by plan. Confirm the member's specific plan covers the home infusion benefit before billing. A claim denial here often means the benefit wasn't verified upfront, not that the service wasn't medically necessary.

4. Always attach Z79.01 as the supporting diagnosis code.

Z79.01 (Long term current use of anticoagulants) is your primary supporting ICD-10 for all four HCPCS codes in this policy. Don't rely on the procedure or surgical diagnosis alone to justify heparin bridging billing. Z79.01 tells the payer's system this is a bridging scenario, not incidental heparin use.

5. Verify prior authorization for inpatient pre-procedure days before admission.

The CPB 0200 Aetna policy cross-references CPB 0255 (Inpatient Admission Prior to Surgery). That connection matters. If you're planning an inpatient pre-procedure stay for bridging, the prior authorization process likely runs through the inpatient admission review, not just the pharmacy or infusion benefit. Get that authorization locked before day one. Retroactive auth requests for inpatient bridging days are a difficult fight.

6. Don't bill J1643 and J1644 interchangeably.

Aetna's code list makes explicit that J1643 is for heparin sodium (Pfizer) and is "not therapeutically equivalent to J1644." If you substitute one for the other based on what's in the formulary that day, you're creating a billing mismatch. Your pharmacy and billing teams need a clean handoff on which product was dispensed.

7. Review related policy CPB 0346 for low-molecular-weight heparin scenarios.

CPB 0200 covers IV heparin bridging. If a physician orders enoxaparin (Lovenox) or another LMWH instead of IV heparin, that falls under CPB 0346. Billing anti-coagulation bridging under the wrong policy is a straight denial. Know which drug is ordered before you assign billing guidelines.

CPT, HCPCS, and ICD-10 Codes for Anti-Coagulant Bridging Under CPB 0200

Covered HCPCS Codes (When Selection Criteria Are Met)

A few things worth knowing about these codes in practice. J1642 is a lock flush dose—tiny quantities used to maintain IV line patency. Don't use it to bill therapeutic heparin infusion. J1644 is your workhorse for therapeutic bridging doses. S9336 is the home infusion administrative services code, which covers the nursing and supply coordination piece—not the drug itself. You may need to bill J1644 separately for the drug component when billing S9336 for home infusion.

Key ICD-10-CM Diagnosis Codes

Z79.01 is the linchpin diagnosis code for all heparin bridging billing under this policy. It tells Aetna's system the member has an established anti-coagulation status that requires management around the surgical or procedural event. Don't let this code fall off a claim because a coder pulled only the surgical diagnosis.

One thing this policy doesn't spell out explicitly: it doesn't list which procedures trigger the bridging review. The policy covers any "diagnostic or therapeutic procedure" where anti-coagulation maintenance is required. That's intentionally broad. In practice, your clinical and billing teams need to make the connection between the procedure being performed and the documented need for bridging. The payer won't make that argument for you.

If you're dealing with a high-volume surgical practice that regularly admits patients on novel oral anti-coagulants (NOACs), this policy affects your pre-admission workflow more than your charge capture. The documentation and prior authorization piece is where denials will come from—not from the codes themselves. Talk to your compliance officer if you're seeing inconsistent inpatient bridging approvals across your Aetna book of business. The criteria language in CPB 0200 is specific enough that a pattern of denials probably traces back to documentation gaps, not policy ambiguity.